Boston Scientific acquires Penumbra for $14.5B — entering neurovascular and mechanical thrombectomy
Summary
Boston Scientific announced the acquisition of Penumbra Inc for $14.5 billion — the largest neurovascular MedTech acquisition ever. Penumbra generated approximately $1.4B in 2025 revenue growing 17%+. The deal gives Boston Scientific scaled entry into mechanical thrombectomy for stroke, peripheral embolization, and neurovascular solutions. Combined with Boston Scientific's existing DBS, SCS, and TMS portfolios, this creates the broadest neurotech product footprint of any MedTech company globally.
Why it matters
A $14.5B neurovascular acquisition from a company that also owns neuromodulation assets signals that Big MedTech views neurology as its next major platform opportunity. Boston Scientific now spans brain stimulation, spinal cord stimulation, TMS, and stroke intervention — no other MedTech company owns all four categories simultaneously.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial